GlassScriptPhysician profile
Peter L Owens
NPI 1528132388
$2,578.79
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,870 · 2020: $619 · 2021: $89.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $995.00 | 2019-2021 | |
| Allergan, INC. | $522.08 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $285.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $180.15 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $154.45 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $125.41 | 2019 | |
| Neurocrine Biosciences, INC. | $118.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.48 | 2019-2020 | |
| Lundbeck LLC | $57.61 | 2019-2020 | |
| Abbvie INC. | $26.37 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.26 | 2019 | |
| Shire North American Group INC | $20.34 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.